ProFuse Technology, a biotechnology company focused on developing muscle therapeutics, has closed a $1.5M pre-seed funding round. The capital is slated to advance selected hits into lead optimization, leveraging the company's proprietary high-throughput human skeletal muscle platform.
Building on scientific breakthroughs from the Weizmann Institute of Science, ProFuse aims to discover first-in-class solutions for sarcopenia and GLP-1-induced muscle loss. Its platform enables predictive, high-throughput screening in physiologically relevant human muscle systems, a significant advancement over traditional models.
